CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD19/CD22 双价 CAR-T 细胞治疗儿童、青少年与年轻成人 B-ALL：1 期试验最终结果

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

靶向 CD79b 的三种新型 CAR 用于非霍奇金淋巴瘤治疗的临床前开发及靶抗原丢失特征分析

Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target

基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。

靶向 CD19/20 的双特异性 CAR-T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者：一项 I/II 期试验

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.

CD19 靶向 CAR-T 细胞治疗后进展的大 B 细胞淋巴瘤的 CD22 靶向 CAR-T 细胞治疗：剂量探索 I 期研究

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.

该试验确定 CD22 是大 B 细胞淋巴瘤的免疫治疗靶点，并证明 CAR22 在 CAR19 治疗后疾病进展患者中具有持久的临床活性。

嵌合抗原受体修饰 T 细胞免疫治疗复发/难治性成人伯基特淋巴瘤

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

儿童和青少年癌症患者 CAR-T 细胞药物研发儿科战略论坛：ACCELERATE 与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i

CAR-T 细胞治疗后出血与血栓形成的发生率及相关危险因素

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.

抗 CD19/CD22、抗 CD19 和抗 CD22 CAR-T 在成人复发/难治性 B 细胞急性淋巴细胞白血病患者中的疗效和安全性差异：一项 meta 分析和系统评价

Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymph

儿童、青少年及年轻成人非霍奇金淋巴瘤的细胞与体液免疫治疗

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.

复发/难治性弥漫大 B 细胞淋巴瘤的新型治疗格局

The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.